{
  "source": "PA-Med-Nec-Cibinqo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2273-5\nProgram Prior Authorization/Medical Necessity\nMedication Cibinqo™ (abrocitinib) tablets\nP&T Approval Date 4/2022, 7/2022, 3/2023, 3/2024, 4/2025\nEffective Date 5/16/2025\n1. Background:\nCibinqo is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric\npatients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose\ndisease is not adequately controlled with other systemic drug products, including biologics, or\nwhen use of those therapies is inadvisable.\nLimitation of Use:\nCibinqo is not recommended in combination with other JAK inhibitors, biologic\nimmunomodulators, or with other immunosuppressants.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Cibinqo will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe chronic atopic dermatitis\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. History of failure, contraindication, or intolerance to two of the following\ntherapeutic classes of topical therapies (document drug, date of trial, and/\nor contraindication to medication):\n(a) Medium, high, or very-high potency topical corticosteroid [e.g., Elocon\n(mometasone furoate), Synalar (fluocinolone acetonide), Lidex\n(fluocinonide)]\n(b) Topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel),\ntacrolimus (generic Protopic)].\n(c) Eucrisa (crisaborole) ¥\n-AND-\nii. One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Both of the following^:\n• Submission of medical records (e.g., chart notes, laboratory values)\ndocumenting a 3 month trial b of a systemic drug product for the\ntreatment of atopic dermatitis [examples include, but are not limited\nto, Adbry (tralokinumab-ldrm), Dupixent (dupilumab), Ebglyss\n(lebrikizumab-lbkz), etc.Ω] (prescription claims history may be used\nin conjunction as documentation of medication use, dose, and\nduration)\n-AND-\n• Phy",
    "ralokinumab-ldrm), Dupixent (dupilumab), Ebglyss\n(lebrikizumab-lbkz), etc.Ω] (prescription claims history may be used\nin conjunction as documentation of medication use, dose, and\nduration)\n-AND-\n• Physician attests that the patient was not adequately controlled with\nthe documented systemic drug product b\n-OR-\nb. Physician attests that systemic treatment with all of the following,\nFDA-approved chronic atopic dermatitis therapies is inadvisable.\n(Document drug and contraindication rationale) ^\n• Adbry (tralokinumab-ldrm)\n• Dupixent (dupilumab)\n• Ebglyss (lebrikizumab-lbkz)\n-OR-\nc. Patient has a documented needle-phobia to the degree that the patient has\npreviously refused any injectable therapy or medical procedure (refer to\nDSM-V-TR 300.29 for specific phobia diagnostic criteria5).\n-OR-\n(b) Both of the following:\ni. Patient is currently on Cibinqo therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Pfizer dermatology\npatient access program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cibinqo*\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(3) Patient is not receiving Cibinqo in combination with any of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Olumiant (baricitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadicitinib), Xeljanz/XR (tofacitinib)]\n(c) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(4) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer sup",
    ") Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\n* Patients requesting initial authorization who were established on therapy via the receipt of\na manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance\nfrom the Pfizer dermatology patient access program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cibinqo will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cibinqo therapy\n-AND-\n(2) Patient is not receiving Cibinqo in combination with any of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab), Ebglyss (lebrikizumab-lbkz), Nemluvio (nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Olumiant (baricitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadicitinib), Xeljanz/XR (tofacitinib)]\n(c) Potent immunosuppressant (e.g., azathioprine, cyclosporine, mycophenolate\nmofetil)\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n3\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n^ Tried/failed alternative(s) are supported by FDA labeling.\n¥ Eucrisa requires prior authorization.\nTable 1: Relative potencies of topical corticosteroids3\nClass Drug Dosage Form Strength (%)\nAugmented betamethasone Ointment, gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, oint",
    " gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cream, lotion 0.05\ndipropionate\nBetamethasone dipropionate Cream, foam, ointment, solution 0.05\nDesoximetasone Cream, ointment 0.25\nHigh Potency Desoximetasone Gel 0.05\nDiflorasone diacetate Cream 0.05\nFluocinonide Cream, gel, ointment, solution 0.05\nHalcinonide Cream, ointment 0.1\nMometasone furoate Ointment 0.1\nTriamcinolone acetonide Cream, ointment 0.5\nBetamethasone valerate Cream, foam, lotion, ointment 0.1\nClocortolone pivalate Cream 0.1\nDesoximetasone Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometasone furoate Cream, lotion 0.1\nTriamcinolone acetonide Cream, ointment, lotion 0.1\nHydrocortisone butyrate Cream, ointment, solution 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonide Cream, gel, foam, ointment 0.05\nFluocinolone acetonide Cream, solution 0.01\nDexamethasone Cream 0.1\nLowest\nHydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1\npotency\nHydrocortisone acetate Cream, ointment 0.5-1\n© 2025 UnitedHealthcare Services, Inc.\n4\nTable 2: Systemic immunomodulatory agents recommended by the 2014 American Academy of\nDermatology guidelines for the treatment of refractory atopic dermatitis Ω,4\nCyclosporine\nAzathioprine\nMethotrexate\nMycophenolate mofetil\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program a",
    "ove initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cibinqo [package insert]. New York, NY: Pfizer Inc.; December 2023.\n2. Eichenfield LF, Tom WL, Chamlin SL et al. Guidelines of care for the management of atopic\ndermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol.\n2014; 70(1):338-51.\n3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic\ndermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am\nAcad Dermatol. 2014; 71(1):116-32.\n4. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic\ndermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am\nAcad Dermatol. 2014 Aug;71(2):327-49.\n5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth\nEdition, Arlington, VA: American Psychiatric Publishing. 2013.\nProgram Prior Authorization/Medical Necessity – Cibinqo (abrocitnib)\nChange Control\n4/2022 New program\n7/2022 Removed age requirement from initial authorization criteria for atopic\ndermatitis. Updated state mandate footnote to include Mississippi.\n3/2023 Updated background to reflect expanded indication for patients 12 years\nof age and older. Updated step requirement to generic Elidel and\nProtopic and removed footnote. Updated reference.\n3/2024 Annual review. Clarified topical steroid potency in atopic dermatitis\nwith no change to clinical intent or coverage criteria. Updated state\nmandate footnote and reference.\n4/2025 Annual review. Added Ebglyss as an example of systemic drug\nproduct. Updated examples with no change to clinical intent.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}